HIGHLIGHTS
· Revenue reached
· Revenue of Abilify Maintena[®] increased 33% to
· Revenue of Brintellix[®]/Trintellix[®] increased 36% to
· Revenue of Northera[®] increased 24% to
· Revenue of Rexulti[®]/Rxulti[®] increased 48% to
· Revenue in
· Revenue in International Markets increased 16% to
· Revenue in
· The four strategic brands grew by 35%, reaching
· Both revenue and earnings are positively impacted by increases in demand and increased stocking related to the ongoing COVID-19 pandemic. The magnitude is, however, difficult to quantify based on current data
· Core EBIT reached
· Reported EBIT reached
· Core EPS reached
· On
· In the quarter, the AMBLED phase IIa study of foliglurax in Parkinson's disease did not show a statistically significant reduction in OFF time (primary endpoint) nor an improvement of dyskinesia (secondary endpoint). Consequently, further development of foliglurax is being terminated
· The financial guidance for 2020 is maintained based on the current assessment of the COVID-19 impact. Lundbeck still expects revenue to reach
In connection with the financial report, Lundbeck's President and CEO
"I am pleased with the strong performance of our brands in this quarter. Demand has been strong, but we also recognize that we have benefitted from patients gaining longer refill prescriptions as well as some stocking of products in many countries in response to the COVID-19 pandemic. These unprecedented times reduce our ability to forecast how these trends will evolve during the year. We are grateful that we have been able to continue to produce our medicines throughout these first months to meet rising needs of patients facing mental health challenges, exacerbated by the pandemic."
DKK million Q1 2020 Q1 2019 Growth
Core Revenue* 4,564 4,234 8%
Core EBIT* 1,357 1,410 (4%)
Core EPS* 4.89 5.48 (11%)
Core EBIT margin* 29.7% 33.3% -
Reported Revenue 4,564 4,234 8%
Reported EBIT 338 1,200 (72%)
Reported EPS 0.76 4.52 (83%)
Reported EBIT margin 7.4% 28.3% -
*For definition of the measures "Core Revenue", "Core EBIT" and "Core EPS", see note 5 Core reporting
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/strong-momentum-across-all-strategic-brands-with-35--growth-in-q1-2020--financial-guidance-maintaine,c3109250
https://mb.cision.com/Main/18215/3109250/1246050.pdf
(c) 2020 Cision. All rights reserved., source